EARLY DIAGNOSIS AND TREATMENT RESEARCH FOUNDATION INC (EIN 264046648) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2009

Legal Domicile

Principal Officer

CLAUDIA HENSCHKE

Tax Period

2023-01-01 to 2023-12-31

EARLY DIAGNOSIS AND TREATMENT RESEARCH FOUNDATION INC, founded in 2009, is a small nonprofit in the Medical Research sector that reported $151K in total revenue in fiscal year 2023. Revenue grew 18% year-over-year, indicating healthy expansion. Expenses of $264K exceeded revenue, resulting in a 74% operating deficit.

Mission

TO FURTHER & SUPPORT RESEARCH IN THE FIELD OF EARLY DIAGNOSIS & TREATMENT OF DISEASE. PRIMARILY ENGAGING IN CONTINUOUS, ACTIVE CONDUCT OF RESEARCH TO DEVELOP THE KNOWLEDGE BASE FOR THE PRACTICE OF SCREENING FOR EARLY DISEASES SUCH AS LUNG CANCER, CHRONIC OBSTRUCTIVE PULMONARY DISEASES & CARDIAC DISEASE. TO HOLD CONFERENCES, CONDUCT STUDIES & REPORT ON RESULTS IN A TIMELY MANNER TO THE MEDICAL COMMUNITY & INTERESTED ADVOCACY ORGANIZATIONS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $53,500

Program Service Revenue $0

Investment Income $97,740

Other Revenue $53

TOTAL REVENUE $151,293

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $223,155

Other Expenses $263,869

TOTAL EXPENSES $263,869

Year-over-Year Comparison

	2023	2022	Change
Revenue	$151,293	$128,721	+0.2%
Expenses	$263,869	$142,489	+0.9%
Net Income	$-112,576	$-13,768	+7.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CLAUDIA HENSCHKE	PRESIDENT, TREASURER	10.00	Officer Director	$0	$0	$0
JANE STANICKI	SECRETARY	1.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$151,293	$263,869	$590,787	$-112,576
2022	$128,721	$142,489	$735,227	$-13,768
2021	$36,013	$121,210	$919,497	$-85,197
2020	$116,276	$106,602	$940,640	$9,674
2019	$301,923	$403,054	$894,727	$-101,131
2018	$349,189	$512,818	$891,017	$-163,629

EARLY DIAGNOSIS AND TREATMENT RESEARCH FOUNDATION INC